Emerald Advisers LLC Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Emerald Advisers LLC acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 146,298 shares of the company's stock, valued at approximately $4,812,000. Emerald Advisers LLC owned about 0.38% of Tarsus Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Swiss National Bank grew its stake in Tarsus Pharmaceuticals by 1.4% during the 1st quarter. Swiss National Bank now owns 42,433 shares of the company's stock valued at $1,542,000 after purchasing an additional 600 shares during the last quarter. Alpha DNA Investment Management LLC increased its holdings in Tarsus Pharmaceuticals by 9.1% in the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company's stock worth $412,000 after buying an additional 1,261 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock worth $166,000 after buying an additional 1,530 shares during the period. Profund Advisors LLC raised its position in Tarsus Pharmaceuticals by 26.8% during the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company's stock worth $248,000 after buying an additional 1,929 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Tarsus Pharmaceuticals during the 2nd quarter valued at approximately $61,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS traded down $1.09 during trading on Monday, reaching $46.21. 705,930 shares of the company's stock traded hands, compared to its average volume of 718,016. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $15.47 and a fifty-two week high of $48.60. The company has a 50-day simple moving average of $34.34 and a 200-day simple moving average of $31.60. The firm has a market cap of $1.76 billion, a PE ratio of -10.31 and a beta of 1.00.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million for the quarter, compared to analysts' expectations of $31.30 million. During the same quarter last year, the company earned ($1.17) EPS. As a group, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current year.

Wall Street Analyst Weigh In

TARS has been the subject of several recent research reports. Oppenheimer reissued an "outperform" rating and set a $63.00 target price (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $51.60.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.